## CITATION REPORT List of articles citing

Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial

DOI: 10.1097/01.ju.0000136448.71773.2b Journal of Urology, 2004, 172, 1036-41.

**Source:** https://exaly.com/paper-pdf/37371297/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
191	Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246		
190	Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. <i>Journal of Sexual Medicine</i> , <b>2004</b> , 1, 161-7	1.1	38
189	Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. <i>European Urology</i> , <b>2004</b> , 45, 123-33	10.2	104
188	Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. <b>2004</b> , 5, 467-71		37
187	New phosphodiesterase inhibitors in the treatment of erectile dysfunction. <b>2004</b> , 5, 2241-9		11
186	Erectile Dysfunction and Radical Prostatectomy: An Update. <b>2004</b> , 2, 84-92		6
185	Phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>BJU International</i> , <b>2005</b> , 96, 257-80	5.6	153
184	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men na le to phosphodiesterase 5 inhibitor therapy. <i>BJU International</i> , <b>2005</b> , 96, 1323-32	5.6	78
183	Recovery of erection after pelvic urologic surgery: our experience. <i>International Journal of Impotence Research</i> , <b>2005</b> , 17, 484-93	2.3	18
182	The therapeutic dilemma: how to use tadalafil. <b>2005</b> , 28 Suppl 2, 74-80		36
181	The efficacy of tadalafil in clinical populations. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 517-31	1.1	56
180	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <i>World Journal of Urology</i> , <b>2005</b> , 23, 374-84	4	25
179	Erectile dysfunction and treatment of carcinoma of the prostate. <b>2005</b> , 6, 461-9		14
178	Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. <b>2005</b> , 50, 2059-62		24
177	Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. <i>BMC Urology</i> , <b>2005</b> , 5, 18	2.2	43
176	Incontinence and erectile dysfunction following radical prostatectomy: a review. <i>Scientific World Journal, The</i> , <b>2005</b> , 5, 747-58	2.2	43
175	Tadalafil: a clinical update. <b>2005</b> , 1, 203-214		3

## (2006-2005)

174	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005, 2, 239-47		40
173	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <b>2005</b> , 6, 75-84		43
172	Phosphodiesterase 5 inhibitors for erectile dysfunction. <b>2005</b> , 39, 1286-95		61
171	Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. <i>Urology</i> , <b>2005</b> , 65, 353-9	6	53
170	Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. <i>Urology</i> , <b>2005</b> , 66, 1080-5	6	34
169	Management of erectile dysfunction after radical prostatectomy. <i>Urology</i> , <b>2005</b> , 66, 923-9 1.	6	19
168	The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. <b>2005</b> , 21, 1701-9		14
167	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <b>2005</b> , 65, 1621-50		133
166	Frequently asked questions about tadalafil for treating men with erectile dysfunction. 2005, 2, 141-157		1
165	PDE-5 inhibitors: current status and future trends. <b>2005</b> , 32, 511-25, viii		25
164	Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. <b>2006</b> , 23, 101-17		37
164			<ul><li>37</li><li>5</li></ul>
ŕ	and pharmacological management. <b>2006</b> , 23, 101-17	6	
163	and pharmacological management. <b>2006</b> , 23, 101-17  Potency after Radical Prostatectomy: From New Techniques to Better Results. <b>2006</b> , 4, 33-45  Anatomic nerve-sparing laparoscopic radical prostatectomy: comparison of retrograde and	6	5
163	and pharmacological management. 2006, 23, 101-17  Potency after Radical Prostatectomy: From New Techniques to Better Results. 2006, 4, 33-45  Anatomic nerve-sparing laparoscopic radical prostatectomy: comparison of retrograde and antegrade techniques. <i>Urology</i> , 2006, 68, 587-91; discussion 591-2	6	5 36
163 162 161	and pharmacological management. 2006, 23, 101-17  Potency after Radical Prostatectomy: From New Techniques to Better Results. 2006, 4, 33-45  Anatomic nerve-sparing laparoscopic radical prostatectomy: comparison of retrograde and antegrade techniques. <i>Urology</i> , 2006, 68, 587-91; discussion 591-2  Sexual function after surgery for prostate or bladder cancer. 2006, 13, 179-87		5 36 17
163 162 161	and pharmacological management. 2006, 23, 101-17  Potency after Radical Prostatectomy: From New Techniques to Better Results. 2006, 4, 33-45  Anatomic nerve-sparing laparoscopic radical prostatectomy: comparison of retrograde and antegrade techniques. <i>Urology</i> , 2006, 68, 587-91; discussion 591-2  Sexual function after surgery for prostate or bladder cancer. 2006, 13, 179-87  Oral Pharmacotherapy of Erectile Dysfunction. 75-93  Comparison of phosphodiesterase type 5 (PDE5) inhibitors. <i>International Journal of Clinical Practice</i> ,	9	<ul><li>5</li><li>36</li><li>17</li><li>5</li></ul>

156	VOICES AND CHOICES: PHYSICIAN, PATIENT, AND PARTNER PERSPECTIVES ON THE MANAGEMENT OF ERECTILE DYSFUNCTION. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 4-9	1.1	
155	Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 419-31	1.1	104
154	Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 650-661	1.1	45
153	Efficacy of tadalafil in men with erectile dysfunction nall we to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 668-675	1.1	14
152	Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. <i>European Urology</i> , <b>2006</b> , 50, 360-5	10.2	63
151	Laparoscopic and robotic assisted radical prostatectomycritical analysis of the results. <i>European Urology</i> , <b>2006</b> , 49, 612-24	10.2	166
150	Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , <b>2006</b> , 50, 351-9	10.2	139
149	Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. <b>2006</b> , 97, 1778-84		63
148	Pharmacology of erectile dysfunction in man. <b>2006</b> , 111, 400-23		44
147	Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. <b>2007</b> , 64, 1584-92		50
146	Treatment of erectile dysfunction: update. <b>2007</b> , 1, 126-38		5
145	The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 55-61	2.3	57
144	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. <b>2007</b> , 34, 507-15, vi		23
143	Disfunci□ li er li ctil tras prostatectom li li radical. <b>2007</b> , 5, 277-283		
142	The sexual impact of cancer and cancer treatments in men. <b>2007</b> , 42, 555-80; vi		19
141	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 281-95	2.3	33
140	Interventions for sexual dysfunction following treatments for cancer. 2007, CD005540		50
139	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <b>2007</b> , 3, 527-542		1

## (2009-2007)

138	Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. <b>2007</b> , 63, 24-35		46
137	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <i>European Urology</i> , <b>2007</b> , 52, 990-1005	10.2	45
136	Management of erectile dysfunction after radical prostatectomy in 2007. <i>World Journal of Urology</i> , <b>2007</b> , 25, 143-8	4	29
135	[Corpus cavernosum rehabilitation after radical urooncological procedures]. 2008, 47, 693-8		2
134	Rehabilitation of erectile function following radical prostatectomy. <i>Asian Journal of Andrology</i> , <b>2008</b> , 10, 61-74	2.8	45
133	Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. <i>BJU International</i> , <b>2008</b> , 102, 426-31	5.6	19
132	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. <i>European Urology</i> , <b>2008</b> , 53, 564-70	10.2	70
131	Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 30-4	2.3	38
130	The cardiovascular safety of tadalafil. <b>2008</b> , 7, 43-52		8
129	Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 554-60	2.3	3
128	Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 60-7	2.3	46
127	The case for postoperative PDE-5 inhibitor drug treatment after radical prostatectomy. <b>2008</b> , 22, 2025-7; discussion 2035		2
126	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. 2008, 5, 355-365		2
125	Tadalafil in the treatment of erectile dysfunction. <b>2008</b> , 4, 1315-30		57
124	Erectile dysfunction following prostatectomy: prevention and treatment. 2009, 6, 415-27		72
123	Penile prosthesis implant: when, what and how. <b>2009</b> , 6, 299-306		
122	Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 1270-83	1.1	36
121	Impaired cavernous reinnervation after penile nerve injury in rats with features of the metabolic syndrome. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 3032-44	1.1	12

120	The management of erectile dysfunction with placebo only: does it work?. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 3440-8	1.1	21
119	Robotic Prostatectomy Vs Laparoscopic Prostatectomy Vs Open Prostatectomy - Which Is Superior? [An Evidence Based Analysis. <b>2009</b> , 6, 136-144		1
118	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. <i>Asian Journal of Andrology</i> , <b>2009</b> , 11, 629-37	2.8	1
117	Toward a new <b>£</b> POCHS optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1214-30	2.9	17
116	Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1231-6	2.9	
115	Optimizing erectile function after radical prostatectomy. <i>BJU International</i> , <b>2009</b> , 103, 430-2	5.6	
114	Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction. <i>Urology</i> , <b>2009</b> , 73, 756-61	1.6	12
113	Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. <b>2009</b> , 69, 1111-6		32
112	Prevention and Management of Postprostatectomy Erectile Dysfunction. <i>European Urology Supplements</i> , <b>2009</b> , 8, 80-87	0.9	3
111	Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. <i>European Urology</i> , <b>2009</b> , 55, 334-47	10.2	124
110	Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?. <b>2009</b> , 19, 303-8		19
109	[Prevention and treatment of erectile dysfunction after radical prostatectomy]. 2009, 150, 831-7		
108	Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. <b>2009</b> , 151, 639-49		58
107	Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. <b>2009</b> , 151, 650-61		137
106	Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3496-501	3.3	4
105	Standards for clinical trials in male sexual dysfunctions. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 414-44	1.1	35
104	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 524-40	1.1	132
103	Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer.		

102	[Erectile dysfunction after radical prostatectomy: pathophysiology, evaluation and treatment]. <i>Progres En Urologie</i> , <b>2010</b> , 20, 172-82	0.9	5
101	Early intervention is important when treating erectile dysfunction associated with radical prostatectomy. <b>2011</b> , 27, 13-17		
100	Re: Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. A. R. McCullough, W. G. Hellstrom, R. Wang, H. Lepor, K. R. Wagner and J. D. Engel. J Urol 2010; 183: 2451-2456. <i>Journal of Urology</i> , <b>2011</b> , 185, 1540-1; author reply 1540-1	2.5	
99	Erectile Dysfunction following Radical Prostatectomy: A Review. <b>2011</b> , 4, 227-242		2
98	Erectile dysfunction after radical prostatectomy: treatment options. <b>2011</b> , 28, 257-66		5
97	Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. <b>2011</b> , 23, 320-30		6
96	Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 2912-23	1.1	22
95	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <b>2011</b> , 33, 1590-608		10
94	Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. <i>European Urology</i> , <b>2011</b> , 60, 1020-6	10.2	23
93	Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , <b>2011</b> , 60, 1105-13	10.2	135
92	Erectile preservation following radical prostatectomy. <i>Therapeutic Advances in Urology</i> , <b>2011</b> , 3, 35-46	3.2	20
91	PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5590-606	3.3	14
90	Considerations in the design of clinical trials for erectile dysfunction. Clinical Investigation, 2012, 2, 733-	745	О
89	Sexual dysfunction following radical prostatectomy. <i>Journal of Andrology</i> , <b>2012</b> , 33, 1143-54		23
88	Endourological procedures and sexual dysfunction: a prospective multivariate analysis. <i>BJU International</i> , <b>2012</b> , 109, 250-3	5.6	7
87	Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. <i>European Urology</i> , <b>2012</b> , 62, 273	-86 <sup>.2</sup>	110
86	Rehabilitation of Erectile Function After Radical Prostatectomy. <i>European Urology Supplements</i> , <b>2013</b> , 12, 18-24	0.9	
85	Penile rehabilitation after radical prostatectomy: what the evidence really says. <i>BJU International</i> , <b>2013</b> , 112, 998-1008	5.6	73

84	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2013</b> , 11, 222-9	1.7	24
83	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 130-71	1.1	117
82	[Drugs for sexual medicine]. <i>Progres En Urologie</i> , <b>2013</b> , 23, 1299-311	0.9	1
81	High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 2774-81	1.1	20
80	Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. <i>BJU International</i> , <b>2013</b> , 112, 844-51	5.6	71
79	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. <i>World Journal of Men?s Health</i> , <b>2013</b> , 31, 83-102	6.8	22
78	CEFAL TA INDUZIDA PELA TADALAFILA - RELATO DE CASO E REVIS DO DA LITERATURA. <i>Revista Milica Da UFPR</i> , <b>2014</b> , 1, 109		
77	Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective. <i>Research and Reports in Urology</i> , <b>2014</b> , 6, 35-41	1.3	6
76	Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. <i>PLoS ONE</i> , <b>2014</b> , 9, e91327	3.7	27
75	Erectile dysfunction associated with surgery for prostate and colorectal cancer. <i>Trends in Urology &amp; Menls Health</i> , <b>2014</b> , 5, 35-39	0.3	
74	Development of UK recommendations on treatment for post-surgical erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 590-608	2.9	24
73	Radical Prostatectomy. <b>2014</b> ,		3
72	Nerve-sparing prostatectomy benefits men with poor preoperative erectile dysfunction. <i>Journal of Robotic Surgery</i> , <b>2014</b> , 8, 299-304	2.9	
71	Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). <i>European Urology</i> , <b>2014</b> , 65, 587-96	10.2	166
70	Psychotherapy: A missing piece in the puzzle of post radical prostatectomy erectile dysfunction rehabilitation. <i>Actas Urolgicas Espalolas (English Edition)</i> , <b>2014</b> , 38, 385-390	0.1	
69	Psychotherapy: a missing piece in the puzzle of post radical prostatectomy erectile dysfunction rehabilitation. <i>Actas Urolgicas Espalolas</i> , <b>2014</b> , 38, 385-90	0.7	5
68	Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men. <i>Scientific Reports</i> , <b>2014</b> , 4, 5801	4.9	12
67	Have rates of erectile dysfunction improved within the past 17 years after radical prostatectomy? A systematic analysis of the control arms of prospective randomized trials on penile rehabilitation.  Andrology, 2015, 3, 661-5	4.2	27

66	Penile rehabilitation after pelvic cancer surgery. Scientific World Journal, The, 2015, 2015, 876046	2.2	7
65	Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study. <i>BMC Urology</i> , <b>2015</b> , 15, 31	2.2	16
64	Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1031	-8	21
63	Tadalafil therapy for erectile dysfunction following prostatectomy. <i>Therapeutic Advances in Urology</i> , <b>2015</b> , 7, 146-51	3.2	3
62	Effect of Tadalafil Once Daily on Penile Length Loss and Morning Erections in Patients After Bilateral Nerve-sparing Radical Prostatectomy: Results From a Randomized Controlled Trial. <i>Urology</i> , <b>2015</b> , 85, 1090-1096	1.6	22
61	Development and validation of a patient-reported outcome measure for stroke patients. <i>Health and Quality of Life Outcomes</i> , <b>2015</b> , 13, 53	3	16
60	Drug therapy for erectile dysfunction. <b>2016</b> , 172-193		
59	Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy. <i>Andrologia</i> , <b>2016</b> , 48, 20-8	2.4	11
58	Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. <i>Scientific Reports</i> , <b>2016</b> , 6, 32853	4.9	5
57	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, 465-88	1.1	110
56	Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. <i>Scandinavian Journal of Urology</i> , <b>2016</b> , 50, 123-7	1.6	42
55	Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). <i>Journal of Sexual Medicine</i> , <b>2017</b> , 14, 297-315	1.1	51
54	Penile Rehabilitation After Radical Pelvic Surgery. <b>2017</b> , 197-208		
53	Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. <i>Actas Urolgicas Espablas (English Edition)</i> , <b>2017</b> , 41, 479-490	0.1	3
52	Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis. <i>Andrology</i> , <b>2017</b> , 5, 863-872	4.2	21
51	Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. <i>Actas Urolgicas Espalolas</i> , <b>2017</b> , 41, 479-490	0.7	21
50	Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis. <i>Clinical Interventions in Aging</i> , <b>2017</b> , 12, 405-412	4	8
49	Erektile Dysfunktion [Abkl] Eung und Therapie. <i>Journal Fur Urologie Und Urogynakologie</i> , <b>2018</b> , 20, 15-19	0	

Techniques to Improve Sexual Function Following Robot-Assisted Radical Prostatectomy. **2018**, 401-407

		2444	
47	Penile rehabilitation for postprostatectomy erectile dysfunction. <i>The Cochrane Library</i> , <b>2018</b> , 10, CD01	245124	12
46	The 2018 Revision to the Process of Care Model for Management of Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , <b>2018</b> , 15, 1434-1445	1.1	23
45	Management of erectile dysfunction. <b>2018</b> , 545-554		
44	Erektile Dysfunktion [Abkl] Bung und Therapie. <i>Journal Fur Urologie Und Urogynakologie</i> , <b>2018</b> , 25, 95-1	00	
43	Section on Women's Health Combined Sections Meeting Posters. <i>Journal of Womenls Health Physical Therapy</i> , <b>2019</b> , 43, E8-E26	0.7	
42	Pharmacodynamics of the agents used for the treatment of erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 121-131	5.5	3
41	Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis. <i>International Journal of Impotence Research</i> , <b>2020</b> ,	2.3	4
40	Generating comprehensive comparative evidence on various interventions for penile rehabilitation in patients with erectile dysfunction after radical prostatectomy: a systematic review and network meta-analysis. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 109-124	2.3	1
39	Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis. <i>Medicine (United States)</i> , <b>2021</b> , 100, e23778	1.8	1
38	Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis. <i>International Journal of Urology</i> , <b>2021</b> , 28, 637-642	2.3	3
37	Rehabilitation. <b>2014</b> , 63-98		O
36	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , <b>2006</b> , 1, 439-49	4	12
35	Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246		1
34	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. <i>Asian Journal of Andrology</i> , <b>2016</b> , 18, 723-31	2.8	8
33	Tadalafil. <b>2005</b> , 27,		
32	Radical Prostatectomy and Other Pelvic Surgeries. <b>2006</b> , 135-154		2
31	Predictive Factor to Regain Erectile Function after Bilateral Nerve Sparing Radical Retropubic Prostatectomy in Korean Men. <i>Korean Journal of Urology</i> , <b>2007</b> , 48, 283		

The Utility of PDE5 Inhibitors After Radical Prostatectomy. 2009, 177-196 30 Rehabilitation. 2009, 283-313 29 Management of Erectile Dysfunction. 134-145 28 Penile Rehabilitation After Robotic Radical Prostatectomy: The Best Strategy. 2011, 361-370 27 26 Medikamente zur Behandlung sexueller Funktionsst \( \text{Eungen.} \) 2012, 751-763 Postoperative Management: Erectile Function. 2014, 167-188 25 Erectile Dysfunction and Penile Rehabilitation After Robot-Assisted Radical Prostatectomy. 2018, 455-462 24 Effects of tadalafil to prevent injury on corpus cavernosum after vascular or nervous peri-prostatic 1.6 23 bundle injury. Experimental model in rats. Acta Cirurgica Brasileira, 2019, 34, e201900901 The Treatments for Intermediate Risk Prostate Cancer. The Korean Journal of Urological Oncology, 0.1 2.2 2019, 17, 22-33 Rehabilitation in der Uroonkologie: Erektile Dysfunktion. Springer Reference Medizin, 2020, 1-9 21 Unsafe Ingredients Included in Malaysian Food Drug Interphase (FDI) Products: Toyyiban 20 0.7 perspective. Malaysian Journal of Halal Research, 2020, 3, 63-68 Rehabilitation. 2007, 203-228 19 18 Medikamente zur Behandlung sexueller Funktionsst [] flungen. 2008, 687-699 Rehabilitation. 2014, 63-98 17 Use of Stem Cells in the Treatment of Erectile Dysfunction. 2021, 347-365 16 Pharmacologic and surgical therapies for sexual dysfunction in male cancer survivors. Translational 15 2.3 Andrology and Urology, **2015**, 4, 148-59 PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic 1 2 14 Prostatectomy. Reviews in Urology, 2005, 7 Suppl 2, S33-8 Sexual dysfunction after radical prostatectomy. Reviews in Urology, 2005, 7 Suppl 2, S3-S10 13 9

12	Advances in the Management of Post-Radical Prostatectomy Erectile Dysfunction: Treatment Strategies When PDE-5 Inhibitors Don Work. <i>Reviews in Urology</i> , <b>2005</b> , 7 Suppl 2, S39-50	1	3
11	Oral and non-oral combination therapy for erectile dysfunction. <i>Reviews in Urology</i> , <b>2007</b> , 9, 99-105	1	7
10	Renewing intimacy: advances in treating erectile dysfunction postprostatectomy. <i>Reviews in Urology</i> , <b>2008</b> , 10, 245-53	1	4
9	Erectile dysfunction. Clinical Evidence, <b>2011</b> , 2011,		3
8	Penile rehabilitation after radical prostatectomy: patientsSattitude and feasibility in China. <i>Translational Andrology and Urology</i> , <b>2013</b> , 2, 4-9	2.3	1
7	Penile Rehabilitation Strategies Among Prostate Cancer Survivors. <i>Reviews in Urology</i> , <b>2015</b> , 17, 58-68	1	
6	Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis <i>Translational Andrology and Urology</i> , <b>2022</b> , 11, 124-138	2.3	1
5	Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study <i>Sexual Medicine</i> , <b>2022</b> , 10, 100508	2.7	1
4	Current trends in erectile rehabilitation after radical prostatectomy: Results from a worldwide survey. <i>Andrologia</i> ,	2.4	0
3	Erectile Dysfunction: Medical Therapy and Rehabilitation. 2023, 35-45		O
2	Erectile Dysfunction in Pelvic Cancer Survivors and Current Management Options. 2023, 12, 2697		0
1	Sexual dysfunctions in breast cancer patients: evidence in context.		O